Top 50 Ai For Computational Biology in Asia

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

Engine Biosciences utilizes machine learning and high-throughput biology to identify genetic interactions within complex disease networks, enabling the development of targeted therapeutics and biomarkers for specific patient populations. This approach significantly accelerates the research and development process for new medical therapies, reducing costs and improving clinical outcomes for a range of solid tumors.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

Utilizes generative AI to design de novo genes and proteins that integrate multiple biological functions into compact therapeutic molecules. This approach addresses unmet medical needs by enabling the development of highly effective treatments with improved efficiency and specificity.

TandemAI provides a physics-based and AI-driven platform that integrates computational analyses with wet lab experimentation to enhance drug discovery workflows. By offering a collaborative workspace and advanced algorithms, TandemAI enables research teams to accelerate the development of new therapeutics more efficiently than traditional methods.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

The startup develops medical artificial intelligence devices that utilize big data collection, processing, and gene mutation analysis to enhance health management and disease prevention. By enabling real-time analysis of endoscopic images, the technology provides critical insights to medical practitioners, improving treatment strategies and patient outcomes.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

The startup operates an artificial intelligence-based healthcare platform that utilizes biomarker discovery technology to create personalized treatment plans for chronic diseases. This approach enables patients to access affordable and effective care, improving their overall health outcomes.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

Scala Biodesign utilizes a one-shot computational platform that combines evolutionary analysis and AI to enhance the stability, yield, and specificity of proteins for therapeutic and industrial applications. This technology addresses the limitations of natural proteins, which often lack the required resilience and efficiency for modern medical and manufacturing needs.

This startup develops an end-to-end integrated microfluidics chip that uses CRISPR-based DNA editing to write, read, and store digital data in bacterial DNA. This technology offers researchers a novel method for high-density, long-term data storage and retrieval.

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

KYAN Therapeutics utilizes its Optim.AI™ ex vivo analytic platform to perform functional precision medicine tests that evaluate drug response using patient-derived cancer cells. This approach addresses the limitations of standard therapies by providing personalized treatment regimens based on the unique sensitivities of each patient's cancer, thereby improving treatment efficacy.

The startup has developed an epigenetics platform that analyzes cancer patients, specifically focusing on Asian cancers, using epigenomic predictive models to generate actionable insights for treatment decisions. This technology enables clinicians to tailor personalized medicine strategies for advanced cancers, improving patient care through data-driven approaches.

Minutia.AI develops probabilistic AI models to simulate the complex interactions within the human gut microbiome, enabling personalized predictions of individual responses to dietary interventions. Their technology addresses the limitations of traditional biomarker approaches by providing granular insights into microbial dynamics and facilitating tailored dietary recommendations for improved health outcomes.

Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.

Provides an AI-powered platform, MoleculeGEN, for de novo drug design and antibody generation, leveraging deep learning and biophysics to create novel small molecules and antibodies tailored to specific disease targets. This approach addresses the challenges of traditional drug discovery by automating hit generation, lead optimization, and toxicity prediction, enabling faster development of treatments for diseases with high unmet medical needs.

HITS develops AI-driven digital solutions for drug discovery, utilizing advanced molecular design and predictive modeling to enhance the efficiency of early-stage drug development. The platform addresses the challenges of traditional drug discovery by providing accurate predictions for drug-protein interactions and optimizing molecular properties, significantly reducing time and costs associated with the development process.

AION Labs is a venture studio that utilizes AI and computational technologies to enhance drug discovery and development processes by integrating extensive pharma data and real-time validation against industry standards. The company addresses inefficiencies in drug development by providing funding, expert collaboration, and structured support for scientists and tech founders tackling specific biopharma challenges.

bitBiome utilizes single-cell sequencing technology to catalog and evolve microbial genomes, creating a diverse database of over 2 billion sequences. This platform addresses the need for unique enzymes and proteins to enhance biomanufacturing processes across various industries, including drug production and sustainable materials development.

Geneyx provides DNA and RNA data analysis and interpretation for whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, enabling rapid transformation of raw genetic data into clinical reports. The platform enhances diagnostic accuracy and efficiency, aiming to eliminate undiagnosed diseases by increasing the diagnostic yield and reducing turnaround times for genetic testing.

The startup develops an AI bioinformatics platform that utilizes big data analytics and predictive modeling to streamline the identification and validation of drug targets. By simplifying complex biomedical data networks, the platform enables biochemists to gain actionable insights for target identification and drug repurposing.

Sravathi AI Technology Pvt Ltd utilizes proprietary AI algorithms and molecular modeling to design and develop drug molecules, polymers, and catalysts, enhancing the efficiency of chemical synthesis and in-vitro screening. The company addresses the challenge of predicting chemical reactions and optimizing yields at atomic and electronic levels, facilitating faster drug discovery and development processes.

AstraGene manufactures in-vitro diagnostic reagents, microbiology media, and molecular biology kits to enhance the accuracy and efficiency of laboratory testing in clinical, food, and veterinary sectors. The company also offers customized AI decision support systems to improve diagnostic processes, serving approximately 150 labs across the UAE and neighboring countries.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

This microbiome-based life sciences company develops healthcare solutions using big data analytics, mathematical modeling, deep learning, and AI. Their technology analyzes the human microbiome to provide insights that support individual health and well-being.

The startup has developed an AI-powered drug discovery platform that utilizes data-driven methodologies to enhance traditional drug design processes. By providing scientists in the pharmaceutical industry with user-friendly AI tools, the platform accelerates research timelines and facilitates the development of novel therapeutics, ultimately aiming to reduce the burden of diseases on patients.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

The startup offers an online analytical platform that utilizes artificial intelligence to provide standardized data and intelligence services related to pharmaceutical drugs, patents, and companies. By delivering customized reports, the platform helps organizations minimize investment risks and enhance compliance with pharmaceutical data regulations.

ProPhet utilizes AI and machine learning to predict protein dynamics and interactions with drug candidates, enabling the identification of small molecules for hard-to-target proteins. This approach addresses the challenge of discovering therapeutics for diseases previously deemed undruggable, enhancing the efficiency and accuracy of early-stage drug discovery.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.

BiotaX utilizes AI-driven computational biology to construct natural microbial communities tailored for specific functions in health, food, agriculture, and climate applications. The platform addresses the challenge of harnessing the vast diversity of uncultured bacteria to develop effective microbial solutions for various industries.

This startup provides a secure and customizable platform for genomic data analysis, optimizing compute architecture and standardizing bioinformatic algorithms for research, academia, and clinical stakeholders. By simplifying the complexities of genomic data processing, it enhances efficiency and accessibility for users in these fields.

This biotechnology company transforms genomic data into actionable insights for healthcare. It leverages GSA Microarray data technology to analyze and interpret genomic information, providing personalized nutrition recommendations and integrated patient management tools.

This biotechnology platform cultivates and optimizes cooperative microbial communities for specific applications. It identifies synergistic relationships between intestinal microorganism strains to create functional combinations, enabling the development of targeted microbial solutions.

BathGenBio utilizes artificial intelligence to analyze extensive biobank data, including genomic and clinical information, to identify novel biomarkers and optimize drug discovery processes. The platform addresses the challenges of precision medicine by enhancing target discovery, drug response prediction, and drug repurposing for medical institutions and biotechnology companies.

Clinlab.AI, Inc. provides an AI-powered platform for managing Physician Office Laboratories (POLs), enabling physicians to conduct clinical chemistry, immunology, and genomic testing with precision. This solution addresses the need for efficient lab operations and enhanced clinical decision-making, allowing practices to deliver personalized patient care while minimizing upfront costs.

Amwise Diagnostic specializes in precision medicine technology that utilizes genomic profiling and biomarker analysis to tailor cancer treatment plans for individual patients. This approach enhances treatment efficacy and minimizes adverse effects by ensuring therapies are specifically matched to the unique genetic makeup of each tumor.

Description: Quanmol Tech develops a molecular quantification platform that utilizes advanced analytical techniques to enhance chemical product design. This technology enables precise measurement of molecular properties, facilitating the development of more effective and tailored chemical solutions. Web Content:

The startup utilizes a systems biology approach to analyze omics data for drug repositioning, enabling the identification of new therapeutic uses for existing pharmaceuticals. This method addresses the challenge of lengthy and costly drug discovery processes by leveraging already commercialized drugs to find unexpected treatments for various diseases.

The startup has developed an AI-based drug discovery engine that analyzes patient genetic data and disease mutations to identify the most effective medication for individual conditions. By comparing molecular and clinical profiles, the platform enhances treatment precision, ultimately improving patient outcomes and quality of life.

AIGEN Sciences is an AI-driven platform that utilizes machine learning algorithms to accelerate drug discovery and development processes. The platform addresses the lengthy and costly nature of traditional drug research by providing data-driven insights that enhance target identification and compound optimization.

This biotech startup utilizes machine learning and artificial intelligence to enhance pathology image analysis for the early detection of nasopharyngeal cancer. By providing scalable technology, the company enables healthcare professionals to identify this cancer type more accurately and efficiently, improving patient outcomes.

Biobab AiBIO utilizes artificial intelligence and Cryo-EM technology to develop novel pharmaceuticals, focusing on enhancing drug discovery efficiency. The company addresses the challenge of slow and costly drug development processes by streamlining molecular analysis and candidate selection.

This startup provides a bioinformatics platform that analyzes single-cell genomic data to help researchers understand disease mechanisms. It offers accessible, expert data analysis tools, enabling clients to advance genomic research for personalized medicine.